GW Pharmaceuticals Ltd.
Porton Down Science Park
Salisbury
Wiltshire
SP4 0JQ
United Kingdom
Tel: 44-1980-619000
Fax: +44-1980-619111
Website: http://www.medicinal-cannabis.org/
Email: jdg@guy.org.uk
282 articles about GW Pharmaceuticals Ltd.
-
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress
11/3/2020
GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the third quarter ended September 30, 2020.
-
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
11/3/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity.
-
GW Pharmaceuticals hopes to bring its cannabis-based treatment nabiximols for multiple sclerosis spasticity to the United States.
-
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020
10/22/2020
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd, 2020 its financial results and operational progress for the third quarter ending September 30th, 2020. GW will also host a conference call the same day at 8:30 a.m. EST. Conference call inf
-
GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
9/23/2020
This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine
-
BioSpace Movers & Shakers, Sept. 11
9/11/2020
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers. -
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors
9/10/2020
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable global pharmaceutical and biotechnology industry experience and executive-level financial leadership to GW’s Board. “I am very pleased to welco
-
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020
9/10/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company will present positive data from two analyses of Phase 3 clinical trials of nabiximols in persons with multiple sclerosis (MS)-associated spasticity
-
GW Pharmaceuticals to Present at Upcoming Investor Conference
9/1/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the following virtual investor conferences: CITI’s 15th Annual BioPharma Virtual Conference 2020 on Thursday, September 10th, 2020 at 4:15pm EDT Morgan Stanl
-
GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress
8/6/2020
GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced financial results and operating progress for the second quarter ended June 30, 2020.
-
FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex
8/3/2020
GW Pharmaceuticals plc along with its U.S. subsidiary Greenwich Biosciences, Inc., announced the U.S. Food and Drug Administration has approved EPIDIOLEX® oral solution to treat seizures associated with tuberous sclerosis complex in patients one year of age and older.
-
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020
7/23/2020
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6th, 2020 its financial results and operational progress for the second quarter ending June 30th, 2020.
-
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
6/30/2020
GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announces the Company’s strategy for bringing its pipeline product nabiximols to the U.S. market.
-
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug
6/23/2020
GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the UK Home Office has reclassified EPIDYOLEX (cannabidiol) as a Schedule 5 drug.
-
GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity
6/4/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW or the Company), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will host a virtual event for investors to provide a review of the U.S. development program and market opportunity for its late stage pipeline product, nabiximols.
-
GW Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
6/2/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10th, 2020 at 1:20pm EDT, which is being held virtually. A live audio webcast of t
-
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress
5/11/2020
GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announces financial results for the first quarter ended March 31, 2020.
-
GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020
5/1/2020
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Bank of America Healthcare Conference 2020 on Tuesday, May 12th, 2020 at 1:40pm EST, which is being held virtually. Live audio webcasts of the presentation a
-
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020
4/21/2020
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 11th, 2020 its financial results for the first quarter ending March 31st, 2020.
-
GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance
4/6/2020
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid platform, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has received notification from the United States Drug Enforcement Administration (DEA) confirming that EPIDIOLEX® (cannabidiol) is no longer subject to the Controlled Substances Act (CSA)